USO 24312

An open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer (TIGOS-LS) (CA245-0004)

Disease Types: Lymphoma & Hematologic

Eligibility Requirements:

Histologically or cytologically confirmed pulmonary LS-SCLC
• Stage I or II disease must have medically inoperable disease
or be unfit for surgery
• Completed concurrent chemotherapy and radiotherapy for LSSCLC without progression within 42 days before date of
randomization
• At least 3 cycles of chemotherapy (platinum-etoposide)
• No prior systemic treatment for LS-SCLC, with the exception
of chemoradiotherapy and PCI
• Sequential chemotherapy and radiotherapy as definitive
treatment for LS-SCLC excluded
• No prior checkpoint inhibitor therapy or fuc-GM-1 vaccine or
any other vaccine targeting ganglioside antigens

For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg